Unknown

Dataset Information

0

Near Miss or Standard of Care? DPYD Screening for Cancer Patients Receiving Fluorouracil.


ABSTRACT: 5-fluorouracil (5-FU) and its pro-drug capecitabine are widely used anticancer agents. Most 5-FU catabolism is dependent on dihydropyrimidine dehydrogenase (DPD) encoded by the DPYD gene, and DPYD variants that reduce DPD function increase 5-FU toxicity. Most DPD deficient patients are heterozygous and can be treated with reduced 5-FU dosing. We describe a patient with a genotype associated with near complete absence of DPD function, and severe and likely fatal toxicity with 5-FU treatment. The patient was treated effectively with alternative systemic therapy. Routine pretreatment DPYD genotyping is recommended by the European Medicines Agency, and guidelines for use of 5-FU in DPD deficient patients are available. However, outside the province of Quebec, routine pretreatment screening for DPD deficiency remains unavailable in Canada. It is likely our patient would have died from 5-FU toxicity under the current standard of care, but instead provides an example of the potential benefit of DPYD screening on patient outcomes.

SUBMITTER: Winquist LE 

PROVIDER: S-EPMC7816174 | BioStudies | 2020-01-01

SECONDARY ACCESSION(S): rs3918290

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5093042 | BioStudies
2014-01-01 | S-EPMC4071869 | BioStudies
2018-01-01 | S-EPMC6043412 | BioStudies
2018-01-01 | S-EPMC6066555 | BioStudies
2019-01-01 | S-EPMC6571425 | BioStudies
2019-01-01 | S-EPMC6533219 | BioStudies
2013-01-01 | S-EPMC3821392 | BioStudies
2014-01-01 | S-EPMC4012613 | BioStudies
2013-01-01 | S-EPMC3817342 | BioStudies
2013-01-01 | S-EPMC3602211 | BioStudies